An Information-Intensive Approach to the Molecular Pharmacology of Cancer
- 17 January 1997
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 275 (5298), 343-349
- https://doi.org/10.1126/science.275.5298.343
Abstract
Since 1990, the National Cancer Institute (NCI) has screened more than 60,000 compounds against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory concentration (GI50) for any single cell line is simply an index of cytotoxicity or cytostasis, but the patterns of 60 such GI50 values encode unexpectedly rich, detailed information on mechanisms of drug action and drug resistance. Each compound's pattern is like a fingerprint, essentially unique among the many billions of distinguishable possibilities. These activity patterns are being used in conjunction with molecular structural features of the tested agents to explore the NCI's database of more than 460,000 compounds, and they are providing insight into potential target molecules and modulators of activity in the 60 cell lines. For example, the information is being used to search for candidate anticancer drugs that are not dependent on intact p53 suppressor gene function for their activity. It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents.Keywords
This publication has 31 references indexed in Scilit:
- Molecular targets in the National Cancer Institute drug screenZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic AgentsJNCI Journal of the National Cancer Institute, 1994
- National Cancer Institute Drug Information System 3D DatabaseJournal of Chemical Information and Computer Sciences, 1994
- Discrimination techniques applied to the NCI in vitro anti‐tumour drug screen: Predicting biochemical mechanism of actionStatistics in Medicine, 1994
- Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDSThe International Journal of Cell Cloning, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cellsBiochemical and Biophysical Research Communications, 1992
- p53 Mutations in Human CancersScience, 1991
- The p53 tumour suppressor geneNature, 1991
- Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE AlgorithmJNCI Journal of the National Cancer Institute, 1989